Literature DB >> 15236978

Why consider vaginal drug administration?

Nancy J Alexander1, Edward Baker, Marc Kaptein, Ulrich Karck, Leslie Miller, Edio Zampaglione.   

Abstract

OBJECTIVE: To review the anatomy and physiology of the vagina, the merits of vaginal drug administration, and the currently available vaginal drug-administration systems.
DESIGN: Review of basic and clinical research. RESULT(S): Although clinicians commonly use topically administered drugs in the vagina, this route for systemic drug administration is somewhat novel. Experience with a variety of products demonstrates that the vagina is a highly effective site for drug delivery, particularly in women's health. The vagina is often an ideal route for drug administration because it allows for the administration of lower doses, steady drug levels, and less frequent administration than the oral route. With vaginal drug administration, absorption is unaffected by gastrointestinal disturbances, there is no first-pass effect, and use is discreet. Knowledge of anatomy, physiology, histology, and immunology of the vagina should allow clinicians to reassure their patients concerning this mode of delivery. Greater understanding and experience by clinicians should lead to increased use and acceptance of the vagina as a route for drug administration. CONCLUSION(S): The safety and efficacy of vaginal administration have been well established. The vaginal route of drug delivery is acceptable and may even be a preferable route of administration for many drugs, particularly hormones, whether for contraception or postmenopausal estrogen therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15236978     DOI: 10.1016/j.fertnstert.2004.01.025

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  46 in total

1.  Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.

Authors:  Regine Sitruk-Ware; Vivian Brache; Robin Maguire; Horacio Croxatto; Narender Kumar; Sushma Kumar; Juan Carlos Montero; Ana Maria Salvatierra; David Phillips; Anibal Faundes
Journal:  Contraception       Date:  2007-04-18       Impact factor: 3.375

Review 2.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 3.  Vaginal drug distribution modeling.

Authors:  David F Katz; Andrew Yuan; Yajing Gao
Journal:  Adv Drug Deliv Rev       Date:  2015-04-28       Impact factor: 15.470

4.  Maternal hormonal contraceptive use and offspring overweight or obesity.

Authors:  E T Jensen; J L Daniels; T Stürmer; W R Robinson; C J Williams; D Moster; P B Juliusson; K Vejrup; P Magnus; M P Longnecker
Journal:  Int J Obes (Lond)       Date:  2014-07-02       Impact factor: 5.095

Review 5.  Progesterone vaginal ring for luteal support.

Authors:  Laurel Stadtmauer; Kay Waud
Journal:  J Obstet Gynaecol India       Date:  2014-11-05

6.  Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.

Authors:  Muneeb Mohideen; Elias Quijano; Eric Song; Yang Deng; Gauri Panse; Wei Zhang; Meredith R Clark; W Mark Saltzman
Journal:  Biomaterials       Date:  2017-08-15       Impact factor: 12.479

Review 7.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

8.  General tissue characteristics of the lower urethral and vaginal walls in the domestic rabbit.

Authors:  Jorge Rodríguez-Antolín; Nicté Xelhuantzi; Mario García-Lorenzana; Estela Cuevas; Robyn Hudson; Margarita Martínez-Gómez
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-09-27

9.  Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).

Authors:  Devorah R Wieder; Lynn Pattimakiel
Journal:  Int J Womens Health       Date:  2010-11-12

10.  Characteristics of women screened for a contraceptive intravaginal ring study in Kisumu, Kenya, 2014.

Authors:  Eleanor McLellan-Lemal; Deborah A Gust; Roman Gvetadze; Melissa Furtado; Fredrick O Otieno; Mitesh Desai; Clement Zeh; Taraz Samandari; Beatrice Nyagol; Esther M Makanga
Journal:  Res J Womens Health       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.